Should You Buy Enact Holdings Inc (ACT) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
ACT is not a good buy right now for a beginner long-term investor who wants to act immediately. The setup is currently neutral-to-slightly bearish (MACD below zero, no proprietary buy signals, and pattern-based probabilities pointing to weakness over the next week). While Wall Street price targets imply moderate upside (low-to-mid teens), the lack of near-term catalysts and softening YoY earnings momentum makes the risk/reward unattractive at today’s pre-market price (~39.28).
Technical Analysis
Price (pre-market): 39.28. Trend/momentum is mixed: MACD histogram is -0.0535 (below 0) and only mildly contracting, which suggests bearish momentum is easing but not yet reversed. RSI(6) ~51.5 is neutral (no clear overbought/oversold edge). Moving averages are converging, consistent with consolidation rather than a strong uptrend. Key levels: Pivot 38.758 is the near-term line in the sand; holding above it keeps the stock range-bound. Immediate resistance is R1 39.698, then R2 40.279; a breakout would need sustained trade above ~39.70–40.30. Supports: S1 37.819 and S2 37.238. Probability model (similar candlestick patterns) also leans negative: ~70% chance of -0.93% next day and -4.08% next week.
Intellectia Proprietary Trading Signals
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Analyst Ratings and Price Target Trends
Recent analyst trend: ratings remain Neutral/Market Perform across major notes, while price targets have generally drifted higher. 2026-01-06 Goldman Sachs: Neutral, PT raised to $45 from $41. 2025-12-18 Keefe Bruyette: Market Perform, PT raised to $43 from $42. 2025-11-07 JPMorgan: Neutral, PT cut to $39 from $40 after Q3.
Wall Street pros: expectation for solid multi-year fundamental improvement and book value growth themes among mortgage insurers; recent PT raises indicate improved confidence on forward returns. Cons: persistent Neutral/Market Perform stance shows analysts don’t see a clear near-term catalyst or enough asymmetric upside; credit risk/macro uncertainty remains the key wildcard. Ownership/trading context: hedge funds and insiders are both described as neutral with no significant recent trends. Politicians/congress: no recent congress trading data available (no signal of influential buying/selling).
Wall Street analysts forecast ACT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACT is 42.25 USD with a low forecast of 40 USD and a high forecast of 45 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast ACT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACT is 42.25 USD with a low forecast of 40 USD and a high forecast of 45 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 40.140
Current: 40.140
